Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antipsychotic Drugs Are Medco's New Personalized Medicine Target

Executive Summary

Medco will launch a research project in November that aims to validate a biomarker that may improve the cost effectiveness of atypical antipsychotics. The pharmacy benefit manager announced a research collaboration with development-stage genetic test developer SureGene on Aug. 24
Advertisement

Related Content

More Patient Registries Needed To Facilitate CER, Medco Exec Says
More Patient Registries Needed To Facilitate CER, Medco Exec Says
Pooled Antipsychotic Data Will Be Mined For Early Response Signals
Pooled Antipsychotic Data Will Be Mined For Early Response Signals
Large Payers, Including CMS, PBMs, Mostly Absent From PCORI Board
Large Payers, Including CMS, PBMs, Mostly Absent From PCORI Board
Vanda’s Fanapt Approval Shows Evolution Of FDA’s Thinking
Vanda’s Fanapt Approval Shows Evolution Of FDA’s Thinking
CATIE Cost-Effectiveness Study Favors Perphenazine Over Atypicals

Topics

Advertisement
UsernamePublicRestriction

Register

PS052573

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel